成纤维细胞生长因子受体抑制剂上市后眼部安全信号分析
基于FAERS数据库2019年4月至2025年6月数据,采用不成比例分析评估厄达替尼、培米替尼和福巴替尼相关的眼部不良事件。共识别1582例FGFR抑制剂相关不良事件,其中200例(12.6%)为眼部事件。厄达替尼信号以角膜变薄、眼毒性和干眼为主,培米替尼以浆液性视网膜脱离、视网膜下液和视网膜色素上皮脱离为主。
要点
- 厄达替尼眼部事件占比最高(75%),角膜变薄ROR 321(95%CI 102-1009)信号最强。
- 培米替尼以浆液性视网膜脱离ROR 180(95%CI 67-484)等视网膜体液相关信号为主。
- 福巴替尼仅报告1例干眼事件,ROR 36.12(95%CI 15.76-82.74)。
核心结论
- 上市后药物警戒分析发现FGFR抑制剂相关眼部不良事件,超出临床试验和监管标签所报告的范围。
- 上述发现属于假设生成性质,反映的是不成比例报告而非发生率或因果风险。
研究设计与样本
- 基于人群的药物警戒研究,数据来源于美国FDA不良事件报告系统(FAERS)。
- 分析2019年4月19日至2025年6月30日数据,使用OpenVigil 2.1工具。
- 纳入接受厄达替尼、培米替尼或福巴替尼治疗的个体眼部不良事件报告。
- 采用不成比例分析计算药物-眼部不良事件配对的报告比值比(ROR),对照为所有其他药物。
主要发现
- 共识别1582例FGFR抑制剂相关不良事件,其中200例(12.6%)为眼部事件。
- 厄达替尼占眼部不良事件的75%,培米替尼占22%,福巴替尼占3%。
- 厄达替尼信号最强的眼部不良事件包括角膜变薄(ROR 321;95%CI 102-1009)、眼毒性(ROR 225;95%CI 117-439)和干眼(ROR 138;95%CI 44-432)。
- 培米替尼信号最强的眼部不良事件包括浆液性视网膜脱离(ROR 180;95%CI 67-484)、视网膜下液(ROR 165;95%CI 68-398)和视网膜色素上皮脱离(ROR 110;95%CI 35-344)。
- 福巴替尼仅报告1例眼部不良事件,为干眼(ROR 36.12;95%CI 15.76-82.74)。
临床怎么用
- 使用厄达替尼时关注角膜变薄、眼毒性和干眼相关症状,必要时进行角膜评估。
- 使用培米替尼时关注浆液性视网膜脱离、视网膜下液和视网膜色素上皮脱离,建议进行眼底检查。
- 上述信号可用于指导临床监测,但需结合患者具体情况,不能作为因果风险或发生率的依据。
局限性
- 研究为药物警戒不成比例分析,结果反映报告偏倚而非真实发生率或因果风险。
- 原文指出发现属于假设生成性质,需进一步研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate postmarketing ocular adverse events (oAEs) associated with fibroblast growth factor receptor inhibitors (FGFRi). DESIGN: Population-based pharmacovigilance study. PARTICIPANTS: Ocular AE reports from the US Food and Drug Administration Adverse Event Reporting System for individuals treated with erdafitinib, pemigatinib, or futibatinib. METHODS: US Food and Drug Administration Adverse Event Reporting System data from April 19, 2019 to June 30, 2025 were analyzed using OpenVigil 2.1. Disproportionality analyses were conducted to calculate reporting odds ratios for drug-oAE pairs compared with all other drugs. MAIN OUTCOME MEASURES: Disproportionality of reported ocular AEs among erdafitinib, pemigatinib, and futibatinib. RESULTS: A total of 1582 FGFR inhibitor-associated adverse events were identified, of which 200 (12.6%) were ocular. Erdafitinib accounted for the majority of ocular adverse events (75%), followed by pemigatinib (22%) and futibatinib (3%). The oAEs reported with the highest disproportionality signal with erdafitinib included corneal thinning (ROR 321; 95% CI 102-1009), ocular toxicity (ROR 225; 95% CI 117-439), and xerophthalmia (ROR 138; 95% CI 44-432). The oAEs with the greatest disproportionality signals with pemigatinib were serous retinal detachment (ROR 180; 95% CI 67-484), subretinal fluid (ROR 165; 95% CI 68-398), and retinal pigment epithelium detachment (ROR 110; 95% CI 35-344). Only 1 oAE was reported for futibatinib, which was dry eye (ROR 36.12; 95% CI 15.76-82.74). CONCLUSIONS: This pharmacovigilance analysis identified oAEs associated with FGFR inhibitors in real-world use, extending beyond those reported in clinical trials and regulatory labeling. However, findings are hypothesis-generating and reflect disproportional reporting rather than incidence or causal risk.
引用
- Abu Osba A, Ahmad S, Abu Osba R, et al. Ocular Safety Signals of Fibroblast Growth Factor Receptor Inhibitors in Postmarketing Surveillance. Am J Ophthalmol. 2026. PMID: 42214582. doi:10.1016/j.ajo.2026.05.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。